"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ES,T3,ES 2883128 T3,084-809-433-869-267,2021-12-07,2021,ES 16843185 T,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,Anticuerpos anti-survivina para la terapia contra el cáncer,"Un anticuerpo que es específico para la survivina para el uso en un método para tratar un tumor que expresa la survivina en un individuo, el uso comprende administrar una composición al individuo que tiene un tumor que expresa la survivina, dicha composición comprende el anticuerpo que es específico para la survivina; en donde el anticuerpo comprende una región variable de cadena pesada y una región variable de cadena ligera, en donde, a) la región variable de cadena pesada comprende una VH CDR1 que comprende la secuencia de SEQ ID NO: 7, una VH CDR2 que comprende la secuencia de SEQ ID NO: 8 y una VH CDR3 que comprende la secuencia de SEQ ID NO: 9, y la región variable de cadena ligera comprende una VL CDR1 que comprende la secuencia de SEQ ID NO: 10, una VL CDR2 que comprende la secuencia de SEQ ID NO: 11 y una VL CDR3 que comprende la secuencia de SEQ ID NO: 12; o b) la región variable de cadena pesada comprende una VH CDR1 que comprende la secuencia de SEQ ID NO: 13, una VH CDR2 que comprende la secuencia de SEQ ID NO: 14 y una VH CDR3 que comprende la secuencia de SEQ ID NO: 15, y la región variable de cadena ligera comprende una VL CDR1 que comprende la secuencia de SEQ ID NO: 16, una VL CDR2 que comprende la secuencia de SEQ ID NO: 17 y una VL CDR3 que comprende la secuencia de SEQ ID NO: 18.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT;;CIESIELSKI MICHAEL,,https://lens.org/084-809-433-869-267,Granted Patent,no,0,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C07K16/18;;C07K16/30;;C12P21/08,,0,0,,,,ACTIVE
2,WO,A1,WO 2018/112469 A1,173-039-912-197-259,2018-06-21,2018,US 2017/0067077 W,2017-12-18,US 201662435368 P,2016-12-16,CIRCULATING SURVIVIN-POSITIVE EXOSOMES,"Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT;;CIESIELSKI MICHAEL,,https://lens.org/173-039-912-197-259,Patent Application,yes,1,0,3,3,1,A61P35/00;;A61K39/0011;;A61K39/00115;;A61K9/127;;G01N33/502;;G01N33/5076;;G01N2800/52;;G01N2800/54;;G01N2800/7028,A61P35/00;;A61K39/00;;C07K16/30;;C12P21/08,,3,3,016-664-313-312-121;;014-393-448-851-064;;065-114-822-032-188,10.1080/2162402x.2015.1008347;;pmc4485717;;26155415;;pmc5069322;;27576783;;10.1007/s00262-016-1890-x;;10.1158/1538-7445.am2017-2725,"MULLER ET AL.: ""Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival"", ONCOIMMUNOLOGY, vol. 4, no. 6, 2015, pages e1008347, XP055510988;;FENSTERMAKER ET AL.: ""Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 65, no. 11, 1 November 2016 (2016-11-01), pages 1339 - 1352, XP036079809;;CIESIELSKI ET AL.: ""Circulating CD 9-GFAP-survivin exosomes during active specific immunotherapy, a potential biomarker for glinma"", PROCEEDINGS; AACR ANNUAL MEETING 2017, 1 April 2017 (2017-04-01), Washington, DC, XP055510998, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/77/13_Supplement/2725.short>",PENDING
3,ES,T3,ES 2529193 T3,186-026-211-896-611,2015-02-17,2015,ES 08796301 T,2008-07-18,US 96120607 P;;US 2008/0070496 W,2007-07-19,Péptidos de survivina como vacunas contra el cáncer,Una composición que comprende un péptido que consiste en la secuencia de SEQ ID NO:6. (DLAQMFFCFKELEGW).,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT,,https://lens.org/186-026-211-896-611,Granted Patent,no,0,0,16,18,0,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,C07K14/47;;A61K38/00;;A61K39/00,,0,0,,,,ACTIVE
4,WO,A1,WO 2022/146887 A1,069-247-056-363-803,2022-07-07,2022,US 2021/0065136 W,2021-12-23,US 202063132964 P,2020-12-31,ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES,Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.,HEALTH RESEARCH INC,FENSTERMAKER ROBERT;;CIESIELSKI MICHAEL,,https://lens.org/069-247-056-363-803,Patent Application,yes,1,0,3,3,27,A61P29/00;;A61P37/00;;C07K16/18;;A61K2039/505;;C07K2317/34,A61P29/00;;A61K39/395;;A61P37/00;;C07K16/18,,2,2,057-572-144-787-343;;055-403-289-115-505,pmc7504892;;32839239;;10.4049/jimmunol.2000482;;pmc4106794;;10.1371/journal.pone.0102231;;25050620,"ZHANG ET AL.: ""The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model"", J IMMUNOL., vol. 205, no. 7, 1 October 2020 (2020-10-01), pages 1743 - 1751, XP055954005;;KUSNER ET AL.: ""Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study"", PLOS ONE, vol. 9, no. 7, 22 July 2014 (2014-07-22), pages 1 - 10, XP055554290",PENDING
5,EP,A4,EP 2178548 A4,109-676-506-612-681,2013-03-06,2013,EP 08796301 A,2008-07-18,US 2008/0070496 W;;US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/109-676-506-612-681,Search Report,no,1,0,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K39/00,,7,6,073-491-867-841-716;;103-861-003-450-71X;;010-966-173-525-285;;021-563-744-755-459;;003-932-083-715-983;;007-989-804-413-698,16485128;;10.1007/s00262-006-0138-6;;15779886;;15153842;;10.1177/107327480401100306;;15603888;;10.1016/j.vaccine.2004.08.007;;pmc2572859;;18438666;;10.1007/s00262-008-0510-9;;20422411;;10.1007/s00262-010-0845-x;;pmc4603658,"MICHAEL J CIESIELSKI ET AL: ""Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 12, 17 February 2006 (2006-02-17), pages 1491 - 1503, XP019422499, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0138-6;;BACHINSKY MARGARET M ET AL: ""Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles."", CANCER IMMUNITY 2005, vol. 5, 2005, pages 6, XP009166585, ISSN: 1424-9634;;FENSTERMAKER R A ET AL: ""Immunotherapeutic strategies for malignant glioma"", CANCER CONTROL, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, TAMPA, US, vol. 11, no. 3, 1 May 2004 (2004-05-01), pages 181 - 191, XP008119219, ISSN: 1073-2748;;OTTO K ET AL: ""Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin"", VACCINE, ELSEVIER LTD, GB, vol. 23, no. 7, 4 January 2005 (2005-01-04), pages 884 - 889, XP027651773, ISSN: 0264-410X, [retrieved on 20050104];;MICHAEL J CIESIELSKI ET AL: ""Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 12, 26 April 2008 (2008-04-26), pages 1827 - 1835, XP019654557, ISSN: 1432-0851, DOI: 10.1007/S00262-008-0510-9;;MICHAEL J CIESIELSKI ET AL: ""Antitumor cytotoxic T-cell response induced by a survivin peptide mimic"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 8, 27 April 2010 (2010-04-27), pages 1211 - 1221, XP019842191, ISSN: 1432-0851;;See also references of WO 2009012460A1",ACTIVE
6,EP,B1,EP 2178548 B1,165-954-081-723-519,2014-12-24,2014,EP 08796301 A,2008-07-18,US 2008/0070496 W;;US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/165-954-081-723-519,Granted Patent,yes,3,0,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,C07K14/47;;A61K38/00;;A61K39/00,,6,0,,,"MICHAEL J CIESIELSKI ET AL: ""Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 12, 17 February 2006 (2006-02-17), pages 1491-1503, XP019422499, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0138-6;;BACHINSKY MARGARET M ET AL: ""Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles."", CANCER IMMUNITY 2005, vol. 5, 2005, page 6, XP9166585, ISSN: 1424-9634;;FENSTERMAKER R A ET AL: ""Immunotherapeutic strategies for malignant glioma"", CANCER CONTROL, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, TAMPA, US, vol. 11, no. 3, 1 May 2004 (2004-05-01), pages 181-191, XP008119219, ISSN: 1073-2748;;OTTO K ET AL: ""Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin"", VACCINE, ELSEVIER LTD, GB, vol. 23, no. 7, 4 January 2005 (2005-01-04), pages 884-889, XP027651773, ISSN: 0264-410X [retrieved on 2005-01-04];;MICHAEL J CIESIELSKI ET AL: ""Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 12, 26 April 2008 (2008-04-26), pages 1827-1835, XP019654557, ISSN: 1432-0851, DOI: 10.1007/S00262-008-0510-9;;MICHAEL J CIESIELSKI ET AL: ""Antitumor cytotoxic T-cell response induced by a survivin peptide mimic"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 8, 27 April 2010 (2010-04-27) , pages 1211-1221, XP019842191, ISSN: 1432-0851",ACTIVE
7,WO,A1,WO 2009/012460 A1,121-659-392-204-902,2009-01-22,2009,US 2008/0070496 W,2008-07-18,US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC;;CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/121-659-392-204-902,Patent Application,yes,2,6,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K39/00,,4,1,073-491-867-841-716,16485128;;10.1007/s00262-006-0138-6,"See also references of EP 2178548A4;;A ET AL., J CLIN ONCOL, vol. 20, 2002, pages 1063 - 8;;CIESIELSKI M. J. ET AL., CANCER IMMUNOLOGY, vol. 55, no. 12, 2006, pages 1491 - 1503;;BACHINSKY MM ET AL., CANCER IMMUN., vol. 22, no. 5:6, 2005",PENDING
8,EP,A1,EP 2178548 A1,153-645-705-518-659,2010-04-28,2010,EP 08796301 A,2008-07-18,US 2008/0070496 W;;US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/153-645-705-518-659,Patent Application,yes,0,0,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,C07K14/47;;A61K38/00;;A61K39/00,,0,0,,,,ACTIVE
9,CN,A,CN 101754768 A,025-501-397-607-225,2010-06-23,2010,CN 200880025203 A,2008-07-18,US 2008/0070496 W;;US 96120607 P,2007-07-19,Survivin peptides as cancer vaccines,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,MICHAEL CIESIELSKI;;FENSTERMAKER ROBERT A,,https://lens.org/025-501-397-607-225,Patent Application,no,0,2,16,18,0,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K39/00,,0,0,,,,ACTIVE
10,CA,A1,CA 2694011 A1,184-392-266-922-722,2009-01-22,2009,CA 2694011 A,2008-07-18,US 96120607 P;;US 2008/0070496 W,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/184-392-266-922-722,Patent Application,no,0,0,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K39/00,,0,0,,,,ACTIVE
11,KR,A,KR 20100051643 A,102-945-099-886-172,2010-05-17,2010,KR 20107002216 A,2008-07-18,US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/102-945-099-886-172,Patent Application,no,0,0,16,18,0,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/16;;A61K39/00;;A61P35/00;;A61P39/00,,0,0,,,,ACTIVE
12,CA,C,CA 2694011 C,123-453-907-032-791,2016-01-12,2016,CA 2694011 A,2008-07-18,US 96120607 P;;US 2008/0070496 W,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/123-453-907-032-791,Granted Patent,no,0,0,16,18,20,A61K38/00;;C07K14/4747;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;A61K39/00115;;A61K38/00;;C07K14/4747;;A61K39/00115,C07K14/47;;A61K38/00;;A61K38/10;;A61K38/17;;A61K39/00;;A61K39/385;;A61P35/00;;A61P37/04;;C07K14/82;;C12N5/0784,,0,0,,,,ACTIVE
13,CN,B,CN 101754768 B,132-687-901-978-103,2013-07-10,2013,CN 200880025203 A,2008-07-18,US 2008/0070496 W;;US 96120607 P,2007-07-19,Survivin peptides as cancer vaccines,,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/132-687-901-978-103,Granted Patent,no,0,0,16,18,0,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K39/00,,0,0,,,,ACTIVE
14,HK,A1,HK 1142813 A1,139-582-520-705-922,2010-12-17,2010,HK 10109286 A,2010-09-28,US 2008/0070496 W;;US 96120607 P,2007-07-19,SURVIVIN PEPTIDES AS CANCER VACCINES,,HEALTH RESEARCH INC,CIESIELSKI MICHAEL;;FENSTERMAKER ROBERT A,,https://lens.org/139-582-520-705-922,Patent Application,no,0,0,16,18,0,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K/;;A61K39/00,,0,0,,,,PENDING
15,EP,A2,EP 3344287 A2,172-835-531-262-273,2018-07-11,2018,EP 16843185 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/172-835-531-262-273,Patent Application,yes,0,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,0,0,,,,ACTIVE
16,DK,T3,DK 3344287 T3,040-955-470-220-52X,2021-07-19,2021,DK 16843185 T,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN-ANTISTOFFER TIL CANCERTERAPI,,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/040-955-470-220-52X,Granted Patent,no,0,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C07K16/18;;C07K16/30;;C12P21/08,,0,0,,,,ACTIVE
17,EP,A1,EP 4271411 A1,197-791-738-013-739,2023-11-08,2023,EP 21916288 A,2021-12-23,US 202063132964 P;;US 2021/0065136 W,2020-12-31,ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES,,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/197-791-738-013-739,Patent Application,yes,0,0,3,3,27,A61P29/00;;A61P37/00;;C07K16/18;;A61K2039/505;;C07K2317/34,A61K39/395;;A61P29/00;;A61P37/00;;C07K16/18,,0,0,,,,PENDING
18,US,A1,US 2011/0268755 A1,012-879-568-023-324,2011-11-03,2011,US 201113100564 A,2011-05-04,US 201113100564 A;;US 17605208 A;;US 96120607 P;;US 33113010 P,2007-07-19,Survivin Peptides For Autoimmune Therapies,Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,HEALTH RESEARCH INC (2011-06-15),https://lens.org/012-879-568-023-324,Patent Application,yes,2,0,2,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P29/00;;A61P37/00;;A61P37/04;;C07K14/4747;;C07K14/4747,A61K38/17;;A61P29/00;;A61P37/00;;A61P37/04,424/185.1,3,3,010-830-276-824-840;;026-234-104-228-081;;098-279-641-846-265,15149507;;10.1111/j.1365-2133.2004.05881.x;;10.1016/s0165-5728(01)00389-7;;11585640;;pmc1065333;;15743483,"O. Simonetti, Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study, 2004, British Journal of Dermatology, 150:940-948.;;M.K Sharief, Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis, 2001, Journal of Neuroimmunology 119:358-364.;;Maria Bokarewa, Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis, 2005, Arthritis Res Ther, 7:R349-358.",ACTIVE
19,AU,B2,AU 2016/318158 B2,052-998-673-278-209,2022-09-15,2022,AU 2016/318158 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,Anti-survivin antibodies for cancer therapy,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/052-998-673-278-209,Granted Patent,no,4,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,0,0,,,,ACTIVE
20,CN,A,CN 108883163 A,110-662-455-069-516,2018-11-23,2018,CN 201680060066 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibodycompositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/110-662-455-069-516,Patent Application,no,7,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,1,0,,,"PAOLA FORTUGNO等: ""Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function"", 《JOURNAL OF CELL SCIENCE》",ACTIVE
21,EP,A4,EP 3344287 A4,052-683-051-550-89X,2019-04-24,2019,EP 16843185 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/052-683-051-550-89X,Search Report,no,3,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,4,3,077-073-696-052-571;;055-271-636-234-76X;;068-767-973-920-243,10.1242/jcs.115.3.575;;11861764;;10.3892/mmr.2014.2729;;25333812;;29540489;;10.1158/1078-0432.ccr-17-2778;;pmc5984688,"FORTUGNO PAOLA ET AL: ""Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function"", JOURNAL OF CELL SCIENCE,, vol. 115, no. 3, 1 February 2002 (2002-02-01), pages 575 - 585, XP002530373, ISSN: 0021-9533;;KEJIAN ZHANG ET AL: ""Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo"", MOLECULAR MEDICINE REPORTS, vol. 11, no. 1, 21 October 2014 (2014-10-21), GR, pages 639 - 644, XP055571016, ISSN: 1791-2997, DOI: 10.3892/mmr.2014.2729;;ROBERT A. FENSTERMAKER ET AL: ""Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo"", CLINICAL CANCER RESEARCH, vol. 24, no. 11, 14 March 2018 (2018-03-14), US, pages 2642 - 2652, XP055570931, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-2778;;See also references of WO 2017041092A2",ACTIVE
22,US,A1,US 2009/0041732 A1,109-553-372-226-645,2009-02-12,2009,US 17605208 A,2008-07-18,US 17605208 A;;US 96120607 P,2007-07-19,Survivin Peptides As Cancer Vaccines,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,HEALTH RESEARCH INC (2009-12-14),https://lens.org/109-553-372-226-645,Patent Application,yes,4,11,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K35/12;;A61K38/00;;A61K39/00;;A61P31/00;;C07K7/00;;C07K14/00;;C12N5/06,424/93.7;;530/326;;530/328;;435/325;;514/13,0,0,,,,ACTIVE
23,US,A1,US 2020/0377613 A1,171-290-182-572-930,2020-12-03,2020,US 202016990622 A,2020-08-11,US 202016990622 A;;US 201816233375 A;;US 201615257324 A;;US 201562214242 P,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/171-290-182-572-930,Patent Application,yes,1,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30;;C07K16/18,,0,0,,,,ACTIVE
24,AU,A1,AU 2016/318158 A1,125-540-169-597-165,2018-04-05,2018,AU 2016/318158 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,Anti-survivin antibodies for cancer therapy,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/125-540-169-597-165,Patent Application,no,0,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,0,0,,,,ACTIVE
25,EP,B1,EP 3344287 B1,133-242-889-767-542,2021-05-26,2021,EP 16843185 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/133-242-889-767-542,Granted Patent,yes,7,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C07K16/18;;C07K16/30;;C12P21/08,,4,0,,,"FORTUGNO PAOLA ET AL: ""Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function"", JOURNAL OF CELL SCIENCE,, vol. 115, no. 3, 1 February 2002 (2002-02-01), pages 575-585, XP002530373, ISSN: 0021-9533;;KEJIAN ZHANG ET AL: ""Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo"", MOLECULAR MEDICINE REPORTS, vol. 11, no. 1, 21 October 2014 (2014-10-21), pages 639-644, XP055571016, GR ISSN: 1791-2997, DOI: 10.3892/mmr.2014.2729;;ROBERT A. FENSTERMAKER ET AL: ""Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo"", CLINICAL CANCER RESEARCH, vol. 24, no. 11, 14 March 2018 (2018-03-14), pages 2642-2652, XP55570931, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-2778;;FORTUGNO ET AL.: 'Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function.' J CELL SCIENCE vol. 115, no. 3, 01 February 2002, pages 575 - 585, XP002530373",ACTIVE
26,US,A1,US 2019/0331667 A1,152-574-910-178-479,2019-10-31,2019,US 201716470197 A,2017-12-18,US 201716470197 A;;US 201662435368 P;;US 2017/0067077 W,2016-12-16,CIRCULATING SURVIVIN-POSITIVE EXOSOMES,"Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2020-10-19),https://lens.org/152-574-910-178-479,Patent Application,yes,0,0,3,3,1,A61P35/00;;A61K39/0011;;A61K39/00115;;A61K9/127;;G01N33/502;;G01N33/5076;;G01N2800/52;;G01N2800/54;;G01N2800/7028,G01N33/50;;A61K9/127;;A61K39/00,,0,0,,,,ACTIVE
27,US,A1,US 2019/0119398 A1,150-943-467-074-859,2019-04-25,2019,US 201816233375 A,2018-12-27,US 201816233375 A;;US 201615257324 A;;US 201562214242 P,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/150-943-467-074-859,Patent Application,yes,1,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30;;C07K16/18,,0,0,,,,ACTIVE
28,WO,A3,WO 2017/041092 A3,012-258-688-574-33X,2017-05-11,2017,US 2016/0050391 W,2016-09-06,US 201562214242 P,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/012-258-688-574-33X,Search Report,yes,4,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,A61K39/00;;A61P35/00;;C12P21/08,,1,1,077-073-696-052-571,10.1242/jcs.115.3.575;;11861764,"FORTUGNO ET AL.: ""Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function."", J CELL SCIENCE, vol. 115, no. 3, 1 February 2002 (2002-02-01), pages 575 - 585, XP002530373",PENDING
29,US,A1,US 2017/0066837 A1,157-477-641-165-668,2017-03-09,2017,US 201615257324 A,2016-09-06,US 201615257324 A;;US 201562214242 P,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/157-477-641-165-668,Patent Application,yes,0,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30,,0,0,,,,ACTIVE
30,US,B2,US 7943138 B2,181-496-015-182-579,2011-05-17,2011,US 17605208 A,2008-07-18,US 17605208 A;;US 96120607 P,2007-07-19,Survivin peptides as cancer vaccines,Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.,HEALTH RESEARCH INC,CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,HEALTH RESEARCH INC (2009-12-14),https://lens.org/181-496-015-182-579,Granted Patent,yes,4,14,16,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P31/00;;A61P35/00;;A61P37/04;;A61P39/00;;C07K14/4747;;C07K14/4747,A61K35/12;;A61K38/08;;A61K38/10;;A61K38/16;;A61K39/00,424/185.1;;424/93.71;;424/277.1;;435/372;;514/19.3;;514/21.4;;514/21.5;;514/21.6;;530/326;;530/327;;530/328,0,0,,,,ACTIVE
31,US,B2,US 11773181 B2,046-570-770-056-03X,2023-10-03,2023,US 202016990622 A,2020-08-11,US 202016990622 A;;US 201816233375 A;;US 201615257324 A;;US 201562214242 P,2015-09-04,Anti-survivin antibodies for cancer therapy,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/046-570-770-056-03X,Granted Patent,yes,12,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/28;;A61K35/17;;A61K39/00;;A61K39/395;;C07K16/18;;C07K16/30;;C12N5/0783;;C12N5/16;;C12N15/113;;C12N15/62,,14,12,077-073-696-052-571;;053-511-741-983-655;;012-513-862-089-432;;035-976-233-926-571;;067-930-331-504-53X;;053-533-004-013-605;;027-477-313-726-928;;029-611-134-469-353;;035-544-165-568-995;;006-131-399-651-997;;055-271-636-234-76X;;068-767-973-920-243,10.1242/jcs.115.3.575;;11861764;;10.1016/b978-0-12-557165-4.50007-0;;8811512;;10.1016/0093-691x(95)00355-c;;10.1002/(sici)1097-4547(19960701)45:1<57::aid-jnr5>3.0.co;2-g;;10.1016/0168-1656(94)90062-0;;7764960;;10.1016/0958-1669(92)90084-v;;1369493;;pmc3815551;;10.1007/978-1-60327-369-5_8;;23912987;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1089/mab.2015.0036;;pmc4685505;;26683180;;pmc3107373;;21463133;;10.1517/14712598.2011.573476;;10.3892/mmr.2014.2729;;25333812;;29540489;;10.1158/1078-0432.ccr-17-2778;;pmc5984688,"Fortugno et al., Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function, J. Cell Science, Feb. 2002, vol. 115, No. 3, pp. 575-585.;;Overbeek, P.A., Factors affecting transgenic animal production, Transgenic Animal Technology, 1994, pp. 96-98.;;Wall, R.J., Transgenic Livestock: Progress and Prospects for the Future, Theriogeneology, 1996, vol. 45, pp. 57-68.;;Houdebine, L.M., Production of pharmaceutical proteins from transgenic animals. Journal of Biotechnology, 1994, vol. 34, pp. 269-287.;;Kappel, C.A, et al., Regulating gene expression in transgenic animals, Current Opinions in Biotechnology, 1992, vol. 3, pp. 548-553.;;Liu, C., Strategies for Designing Transgenic DNA Constructs, Methods Mol Biol., Nov. 3, 2013, vol. 1027, pp. 1-17.;;Paul, W.E., Structure and Function of Immunoglobulins, Fundamental Immunology 3rd Edition, 1993, pp. 292-295.;;Rudikoff, S., et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, Mar. 1982, vol. 79, pp. 1979-1983.;;Colman, P.M., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994, vol. 145, pp. 33-36.;;Bendig, M.M., Humanization of Rodent Monoclonal Antibodies by CDR Grafting, Methods: A Companion to Methods in Enzymology, 1995, vol. 8, pp. 83-93.;;Hantasup, K., et al., Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Dec. 18, 2015, vol. 34, No. 6, pp. 404-417.;;Ramos, C.A., et al., Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy, Expert Opinion on Biological Therapy, Apr. 4, 2011, vol. 11, No. 7, pp. 855-873.;;Zhang et al., Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo. Molecular Medicine Reports, vol. 11, No. 1, pp. 639-644. 2014.;;Fenstermaker et al., Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo, Clinical Cancer Research, vol. 24, No. 11, pp. 2642-2652. 2018.",ACTIVE
32,US,B2,US 10738129 B2,054-479-949-574-913,2020-08-11,2020,US 201816233375 A,2018-12-27,US 201816233375 A;;US 201615257324 A;;US 201562214242 P,2015-09-04,Anti-survivin antibodies for cancer therapy,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/054-479-949-574-913,Granted Patent,yes,8,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/18;;A61K35/17;;A61K39/00;;C07K16/30;;C12N5/0783;;C12N5/10;;C12N5/16;;C12N15/113;;C12N15/62,,14,11,053-511-741-983-655;;012-513-862-089-432;;035-976-233-926-571;;067-930-331-504-53X;;027-477-313-726-928;;029-611-134-469-353;;035-544-165-568-995;;006-131-399-651-997;;077-073-696-052-571;;055-271-636-234-76X;;068-767-973-920-243,10.1016/b978-0-12-557165-4.50007-0;;8811512;;10.1016/0093-691x(95)00355-c;;10.1002/(sici)1097-4547(19960701)45:1<57::aid-jnr5>3.0.co;2-g;;10.1016/0168-1656(94)90062-0;;7764960;;10.1016/0958-1669(92)90084-v;;1369493;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1089/mab.2015.0036;;pmc4685505;;26683180;;pmc3107373;;21463133;;10.1517/14712598.2011.573476;;10.1242/jcs.115.3.575;;11861764;;10.3892/mmr.2014.2729;;25333812;;29540489;;10.1158/1078-0432.ccr-17-2778;;pmc5984688,"Overbeek , “Factors affecting transgenic animal production,” Transgenic animal technology, 1994, pp. 96-98.;;Wall, Theriogenology, 1996, vol. 45, pp. 57-68.;;Houdebine, J. Biotech. 1994, vol. 34, pp. 269-287.;;Kappell, Current Opinions in Biotechnology, 1992, vol. 3, pp. 548-553.;;Liu et al., Methods Mol Biol. 2013, 1027: 1-17.;;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, 79(6):1979-1983.;;Colman, Research in Immunology, 1994, 145:33-36.;;Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.;;Khantasup et al., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34(6): 404-417.;;Ramos et al., Expert Opin. Biol. Ther., 2011, 11(7): 855-873.;;Fortugno et al., Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function, J. Cell Science, Feb. 2002, vol. 115, No. 3, pp. 575-585.;;Zhang et al., Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo, Molecular Medicine Reports, vol. 11, No. 1, pp. 639-644 Oct. 21, 2014.;;Fenstermaker et al., Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo, Clinical Cancer Research, vol. 24, No. 11, pp. 2642-2652 Mar. 14, 2018.",ACTIVE
33,US,B2,US 10167340 B2,178-568-505-623-826,2019-01-01,2019,US 201615257324 A,2016-09-06,US 201615257324 A;;US 201562214242 P,2015-09-04,Anti-survivin antibodies for cancer therapy,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2016-10-13),https://lens.org/178-568-505-623-826,Granted Patent,yes,6,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30;;A61K39/00;;A61K39/395;;C07K16/18,,1,1,077-073-696-052-571,10.1242/jcs.115.3.575;;11861764,"Fortugno et al., Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function, J. Cell Science, vol. 115, No. 3, pp. 575-585. Feb. 1, 2002.",ACTIVE
34,WO,A2,WO 2017/041092 A2,127-971-438-421-780,2017-03-09,2017,US 2016/0050391 W,2016-09-06,US 201562214242 P,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/127-971-438-421-780,Patent Application,yes,5,1,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30,,6,5,074-482-128-967-974;;017-090-382-753-584;;062-158-043-867-309;;050-410-930-829-858;;021-725-851-294-394,25073855;;10.1038/srep05885;;pmc4115235;;10.1073/pnas.86.10.3833;;2726754;;pmc287235;;7737671;;10.1089/hyb.1994.13.469;;15646045;;10.2174/1386207053258532;;15777175,"DODEV TS ET AL., SCIENTIFIC REPORTS, vol. 4, 2014, pages 5885;;ORLANDI ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 3833;;LEUNG ET AL., HYBRIDOMA, vol. 13, 1994, pages 469;;MANCINI ET AL., NEW MICROBIOL., vol. 27, 2004, pages 315 - 28;;CONRADSCHELLER, COMB. CHEM. HIGH THROUGHPUT SCREEN., vol. 8, 2005, pages 117 - 26;;See also references of EP 3344287A4",PENDING
35,US,B2,US 8580269 B2,072-097-597-277-016,2013-11-12,2013,US 201113100564 A,2011-05-04,US 201113100564 A;;US 17605208 A;;US 96120607 P;;US 33113010 P,2007-07-19,Survivin peptides for autoimmune therapies,Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used.,CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A;;HEALTH RESEARCH INC,CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,HEALTH RESEARCH INC (2011-06-15),https://lens.org/072-097-597-277-016,Granted Patent,yes,7,4,2,18,20,A61K39/00115;;A61K38/00;;A61K38/00;;A61K39/00115;;A61P29/00;;A61P37/00;;A61P37/04;;C07K14/4747;;C07K14/4747,A61K38/00;;A61K38/17;;A61P29/00;;A61P37/00;;A61P37/04,424/185.1;;424/810;;424/93.71;;514/18.9;;514/17.9;;514/16.6;;514/21.6;;514/21.5;;530/326;;530/327;;530/328;;530/868,9,9,010-830-276-824-840;;026-234-104-228-081;;098-279-641-846-265;;073-491-867-841-716;;103-861-003-450-71X;;010-966-173-525-285;;021-563-744-755-459;;003-932-083-715-983;;007-989-804-413-698,15149507;;10.1111/j.1365-2133.2004.05881.x;;10.1016/s0165-5728(01)00389-7;;11585640;;pmc1065333;;15743483;;16485128;;10.1007/s00262-006-0138-6;;15779886;;15153842;;10.1177/107327480401100306;;15603888;;10.1016/j.vaccine.2004.08.007;;pmc2572859;;18438666;;10.1007/s00262-008-0510-9;;20422411;;10.1007/s00262-010-0845-x;;pmc4603658,"O. Simonetti, Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study, 2004, British Journal of Dermatology, 150:940-948.;;M.K Sharief, Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis, 2001, Journal of Neuroimmunology 119:358-364.;;Maria Bokarewa, Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis, 2005, Arthritis Res Ther, 7:R349-358.;;Ciesielski, et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliornas Cancer Immunology, vol. 55, No. 12, Feb. 17, 2006, pp. 1491-1503.;;Bachinsky, et al. ""Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles."" Cancer Immunity 2005,vol. 5, 2005, p. 6.;;Fenstermaker R A et al: ""Immunotherapeutic strategies for malignant glioma"", Cancer Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa, US, vol. 11, No. 3, May 1, 2004, pp. 181-191.;;Otto K et al: ""Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin"" Vaccine, vol. 23, No. 7, Jan. 4, 2005, pp. 884-889.;;Ciesielski et al.""Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma"", Cancer Immunology, vol. 57, No. 12, Apr. 26, 2008, pp. 1827-1835.;;Ciesielski et al. ""Antitumor cytotoxic T-cell response induced by a survivin peptide mimic"", Cancer Immunology, vol. 59, No. 8, Apr. 27, 2010, pp. 1211-1221.",ACTIVE
36,CA,A1,CA 3203732 A1,195-164-297-986-715,2022-07-07,2022,CA 3203732 A,2021-12-23,US 202063132964 P;;US 2021/0065136 W,2020-12-31,ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES,Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.,HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/195-164-297-986-715,Patent Application,no,0,0,3,3,0,A61P29/00;;A61P37/00;;C07K16/18;;A61K2039/505;;C07K2317/34,A61K39/395;;A61P29/00;;A61P37/00;;C07K16/18,,0,0,,,,PENDING
37,KR,A,KR 20180042431 A,111-388-572-875-899,2018-04-25,2018,KR 20187009445 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,암 치료용 안티-서비빈 항체,"서비빈 특이적 항체, 항체를 인코딩하는 핵산 및 항체 투여에 의해 서비빈-발현 세포를 포함하는 종양의 치료방법이 제공된다. 항체 조성물은 종양의 성장을 저해하는 데에 효과적인 것을 찾아냈다.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/111-388-572-875-899,Patent Application,no,0,0,21,21,0,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/18;;A61K39/00;;C07K16/30,,0,0,,,,DISCONTINUED
38,CA,A1,CA 2997103 A1,107-381-691-947-633,2017-03-09,2017,CA 2997103 A,2016-09-06,US 201562214242 P;;US 2016/0050391 W,2015-09-04,ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY,"Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,,https://lens.org/107-381-691-947-633,Patent Application,no,0,0,21,21,27,C07K16/18;;C07K2317/34;;C07K2317/92;;A61K2039/505;;C07K16/30;;A61P35/00;;C07K16/18;;C07K16/30;;C07K2317/14;;C07K2317/34;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/34;;C07K2317/92;;C12N15/1136;;C12N15/62;;A61K35/17;;C12N5/16;;C12N2510/00;;C12N5/0636;;A61K2039/505;;C07K16/30;;C07K2317/14;;C07K2317/56,C07K16/30;;A61P35/00;;C12P21/08,,0,0,,,,PENDING
39,US,B2,US 11467152 B2,145-193-167-237-686,2022-10-11,2022,US 201716470197 A,2017-12-18,US 201716470197 A;;US 201662435368 P;;US 2017/0067077 W,2016-12-16,Circulating survivin-positive exosomes,"Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.",HEALTH RESEARCH INC,FENSTERMAKER ROBERT A;;CIESIELSKI MICHAEL J,HEALTH RESEARCH INC (2020-10-19),https://lens.org/145-193-167-237-686,Granted Patent,yes,2,0,3,3,1,A61P35/00;;A61K39/0011;;A61K39/00115;;A61K9/127;;G01N33/502;;G01N33/5076;;G01N2800/52;;G01N2800/54;;G01N2800/7028,G01N33/50;;A61K9/127;;A61K39/00,,3,2,016-664-313-312-121;;014-393-448-851-064,10.1080/2162402x.2015.1008347;;pmc4485717;;26155415;;pmc5069322;;27576783;;10.1007/s00262-016-1890-x,"Muller, L., et al., Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival, Oncoimmunology, Jun. 2015, vol. 4, No. 6, e1008347, 8 pages.;;Fenstermaker, R.A., et al., Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma, Cancer Immunol Immunother, Aug. 30, 2016, vol. 65, pp. 1339-1352.;;Ciesielski, M.J., et al., Circulating CD9-GFAP-survivin exosomes during active specific immunotheraphy, a potential biomarker for glioma, Proceedings: AACR Annual Meeting, Jul. 2017, vol. 77, No. 13, 4 pages.",ACTIVE
40,ES,T3,ES 2645367 T3,105-641-054-281-088,2017-12-05,2017,ES 11769246 T,2011-03-11,US 32486610 P;;US 2011/0028202 W,2010-04-16,Composiciones y métodos para la prevención y el tratamiento del cáncer,"Una composición farmacéutica que comprende un compuesto o una sal, solvato o hidrato farmacéuticamente aceptable del mismo, en la que el compuesto está presente en una cantidad desde aproximadamente 100 mg a aproximadamente 400 mg en la composición.",ATHENEX INC,HANGAUER DAVID;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,,https://lens.org/105-641-054-281-088,Granted Patent,no,0,0,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,0,0,,,,ACTIVE
41,CN,A,CN 107441097 A,188-840-624-145-399,2017-12-08,2017,CN 201710480505 A,2011-03-11,US 32486610 P;;CN 201180025212 A,2010-04-16,Compositions And Methods For The Prevention And Treatment Of Cancer,"The invention relates to compositions and methods for prevention and treatment of cancer, and especially relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.",ATHENEX INC,HANGAUER DAVID;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,,https://lens.org/188-840-624-145-399,Patent Application,no,5,0,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/5377;;A61P35/00,,0,0,,,,DISCONTINUED
42,EP,A2,EP 2558085 A2,099-883-248-251-166,2013-02-20,2013,EP 11769246 A,2011-03-11,US 32486610 P;;US 2011/0028202 W,2010-04-16,COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,"ATHENEX, INC. (2017-12-20);;ATNX SPV, LLC; US (2023-07-05);;ATNX SPV, LLC, BUFFALO, US (2023-03-02);;ATNX SPV, LLC. (2023-06-08)",https://lens.org/099-883-248-251-166,Patent Application,yes,0,1,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,0,0,,,,ACTIVE
43,EP,B1,EP 2558085 B1,064-169-432-351-046,2017-08-30,2017,EP 11769246 A,2011-03-11,US 32486610 P;;US 2011/0028202 W,2010-04-16,COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER,,ATHENEX INC,HANGAUER DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,"ATHENEX, INC. (2017-12-20);;ATNX SPV, LLC; US (2023-07-05);;ATNX SPV, LLC, BUFFALO, US (2023-03-02);;ATNX SPV, LLC. (2023-06-08)",https://lens.org/064-169-432-351-046,Granted Patent,yes,0,0,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,2,1,064-095-005-847-857,17942826;;10.1096/fj.07-9574lsf,"REAGAN-SHAW S ET AL: ""Dose translation from animal to human studies revisited"", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 22, 1 January 2007 (2007-01-01), pages 659 - 661, XP007916336, ISSN: 0892-6638;;GAIL ET AL: ""Dose Finding in Drug Development"", 2006, SPRINGER, USA, pages: 1 - 31",ACTIVE
44,EP,A4,EP 2558085 A4,085-727-277-973-624,2013-10-09,2013,EP 11769246 A,2011-03-11,US 32486610 P;;US 2011/0028202 W,2010-04-16,COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER,,KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,"ATHENEX, INC. (2017-12-20);;ATNX SPV, LLC; US (2023-07-05);;ATNX SPV, LLC, BUFFALO, US (2023-03-02);;ATNX SPV, LLC. (2023-06-08)",https://lens.org/085-727-277-973-624,Search Report,no,0,0,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,2,0,,,No further relevant documents disclosed;;See also references of WO 2011129936A2,ACTIVE
45,CA,C,CA 2796419 C,144-733-302-154-903,2018-11-06,2018,CA 2796419 A,2011-03-11,US 32486610 P;;US 2011/0028202 W,2010-04-16,COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER,"The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders. In one aspect the invention concerns a pharmaceutical composition comprising a compound according to the formula: (see above formula) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.",KINEX PHARMACEUTICALS LLC,HANGAUER DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,,https://lens.org/144-733-302-154-903,Granted Patent,no,0,0,14,14,0,A61K31/5377;;A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00;;A61K31/137;;A61K31/496;;A61K31/4418;;A61K31/5375,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,0,0,,,,ACTIVE
46,US,A1,US 2011/0281872 A1,039-905-149-370-045,2011-11-17,2011,US 201113046533 A,2011-03-11,US 201113046533 A;;US 32486610 P,2010-04-16,COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER,The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.,HANGAUER JR DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A;;KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/039-905-149-370-045,Patent Application,yes,5,7,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/165;;A61K31/44;;A61K31/4418;;A61K31/4545;;A61K31/495;;A61K31/496;;A61K31/506;;A61K31/5375;;A61K31/5377;;A61P35/00;;C07C233/22;;C07D213/56;;C07D295/155;;C07D401/04;;C07D401/06;;C07D401/10;;C07D401/12;;C07D403/12;;C07D413/04;;C07D413/06;;C07D413/10;;C07D413/12,514/235.8;;564/161;;546/337;;546/335;;546/194;;544/131;;544/360;;544/295;;544/122;;544/400;;544/168;;544/296;;546/268.4;;514/617;;514/357;;514/318;;514/237.2;;514/253.01;;514/351;;514/235.5;;514/252.14;;514/252.12;;514/238.2;;514/252.18;;514/340,3,0,,,"Smith et al. CAS: 146: 229329, 2007.;;Revarello et al. CAS: 141: 81703, 2004.;;Maeda et al. CAS: 141: 199479, 2004.",ACTIVE
47,US,B2,US 8748423 B2,143-196-191-287-967,2014-06-10,2014,US 201113046533 A,2011-03-11,US 201113046533 A;;US 32486610 P,2010-04-16,Compositions and methods for the prevention and treatment of cancer,The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.,HANGAUER JR DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT ALAN;;KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT ALAN,ATHENEX INC (2015-08-26);;ATNX SPV LLC (2022-06-29),https://lens.org/143-196-191-287-967,Granted Patent,yes,65,14,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/535,514/235.8;;514/617;;514/357;;544/131;;544/360;;546/337,41,32,006-865-227-309-741;;003-705-303-423-094;;102-717-041-069-263;;016-326-088-221-108;;042-874-809-879-621;;101-726-729-921-07X;;093-514-661-071-28X;;048-203-518-030-581;;014-892-315-361-770;;024-246-415-334-792;;013-644-197-083-407;;021-598-187-422-693;;029-742-983-481-795;;133-545-268-130-061;;014-944-545-982-558;;056-481-350-704-182;;017-937-967-857-021;;041-703-940-947-068;;085-441-379-277-757;;083-766-165-487-727;;016-856-688-460-880;;008-506-871-340-22X;;014-281-294-082-381;;002-209-090-598-253;;196-137-673-224-806;;001-516-175-552-397;;045-942-893-332-610;;059-992-524-705-606;;002-214-591-966-495;;158-437-721-422-53X;;064-095-005-847-857;;047-625-573-886-466,10.1021/ja00103a048;;2768367;;10.1016/s0021-9673(01)96453-2;;10.1055/s-1994-25659;;10.1016/0005-2728(95)00131-x;;8573592;;10.1080/10826079508013972;;10.1002/chin.200334072;;5748697;;10.1021/jm00311a010;;10.1007/s11864-001-0072-y;;12057096;;15362850;;10.1021/bi0495073;;11102447;;10.1074/jbc.m008368200;;12020799;;10.1016/s0304-419x(02)00040-9;;10.1002/jhet.5570180707;;10.1126/science.286.5439.531;;10521349;;pmc6757905;;12122079;;10.1523/jneurosci.22-14-06208.2002;;20026599;;10.1021/jm049876x;;15369401;;10.1021/jm00364a026;;6137568;;1875332;;10.1021/jm00112a001;;9544425;;10.1023/a:1005960822365;;10.1002/chin.200429087;;10.1021/jm00023a009;;7473597;;14739300;;10.1074/jbc.m311032200;;10.1517/13543776.15.9.1183;;10.1038/84675;;11175854;;17186241;;10.1007/s00280-006-0398-z;;10.1021/cen-v081n008.p032;;10.1016/s0169-409x(01)00097-7;;11325474;;pmc33604;;10.1073/pnas.96.14.7697;;10393883;;10.1016/j.bmcl.2003.11.079;;15013006;;11689083;;10.1021/jm0102250;;10.1080/00397918008069330;;17942826;;10.1096/fj.07-9574lsf;;15585638;;10.1158/1078-0432.ccr-04-0621,"Smith et al. CAS: 146: 229329, 2007.;;Revarello et al. CAS: 141: 81703, 2004.;;Maeda et al. CAS: 141: 199479, 2004.;;Backes et al. ""Carbon-Carbon Bond-Forming Methods on Solid Support."" J. Am. Chem. Soc. 116.24(1994):11171-11172.;;Blessington et al. ""Chromatographic Approaches to the Quality Control of Chiral Propionate Anti-Inflammatory Drugs and Herbicides."" J. Chromatography. 469(1989):183-190.;;Satoh et al. ""An Efficient Synthesis of 4-aryl-2,6-di-tert-butylphenols by a Palladium-Catalyzed Cross-Coupling Reaction."" Synthesis. 11(1994):1146-1148.;;Satoh et al. ""Comparison of the Inhibitory Action of Synthetic Capsaicin Analogs With Various NADH-Ubiquinone Oxidoreductases."" Biochem. Biophys. Acta. 1273.1(1996):21-30.;;Van Overbeke et al. ""Comparative Study on the Enantiomeric Separation of Several Non-Steroidal Anti-Inflammatory Drugs on Two Cellulose-Based Chiral Stationary Phases."" J. Liquod Chromatography. 18.12(1995):2427-2443.;;An et al. ""Oxidation of N-Benzylaldimines to N-Benzylamides by MCPBA and BF3OEt2."" Synlett. (2003):876-878.;;Byrn et al. ""Solid-State Chemistry of Drugs."" Second Edition. (1999):233-247.;;Cain et al. ""Potential Antitumor Agents."" J. Med. Chem. 11.5(1968):963-966.;;Croteau et al. ""Adults with Newly Diagnosed High-Grade Gliomas."" Current Treatment Options in Oncology. 2(2001):507-515.;;Davidson et al. ""Discovery and Characterization of a Substrate Selective p38alpha Inhibitor."" Biochemistry. 43(2004):11658-11671.;;Duong et al. ""Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-Tyrosine Kinase 2."" J. Biol. Chem. 276.10(2001):7484-7492.;;Frame. ""Src in Cancer: Deregulation and Consequences for Cell Behaviour."" Biochem. Biophys. Acta. 1602(2002):114-130.;;Garrido et al. ""Synthesis of N,N'-Diacyl-1,2-di-(4-pyridyl)ethylenediamines."" J. Het. Chem. 18(1981):1305-1308.;;Golub et al. ""Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring."" Science. 286(1999):531-537.;;Guo et al. ""Tyrosine Phosphorylation of the NR2B Subunit of the NMDA Receptor in the Spinal Cord During the Development and Maintenance of Inflammatory Hyperalgesia."" J. Neurosci. 22.14(2002):6208-6217.;;Hadjeri et al. ""Antimitotic Activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones."" J. Med. Chem. 47(2004):4964-4970.;;Han. ""Advances in Characterization of Pharmaceutical Hydrates."" Trends in Bio/Pharmaceutical Industry. 3(2006):25-29.;;Honma et al. ""Antiallergic Agents."" J. Med. Chem. 26(1983):1499-1504.;;Huff. ""HIV Protease: A Novel Chemotherapeutic Target for AIDS."" J. Med. Chem. 34.8(1991):2305-2314.;;Lala et al. ""Role of Nitric Oxide in Tumor Progression: Lessons from Experimental Tumors."" Cancer Metastasis Rev. 17.1(1998):91-106.;;Liechti et al. ""Salicylanilides as Inhibitors of the Protein Tyrosine Kinase Epidermal Growth Factor Receptor."" Eur. J. Med. Chem. 39.1(2004):11-26.;;Million et al. ""Inhibition of the EGF-Stimulated Cellular Proliferation of ER 22 Cells by Hydroxybiphenyl Derivatives."" J. Med. Chem. 38.23(1995):4693-4703.;;Miyazaki et al. ""Src Kinase Activity is Essential for Osteoclast Function."" J. Biol. Chem. 279.17(2004):17660-17666.;;Parang et al. ""Recent Advances in the Discovery of Src Kinase Inhibitors."" Expert Opin. Ther. Patents. 15.9(2005):1183-1207.;;Paul et al.A ""Src Deficiency or Blockade of Src Activity in Mice Provides Cerebral Protection Following Stroke."" Nat. Med. 7.2(2001):222-227.;;Planas-Silva et al. ""Targeting c-Src Kinase Enhances Tamoxifen's Inhibitory Effect on Cell Growth by Modulating Expression of Cell Cycle and Survival Proteins."" Cancer Chemotherapy Pharmacol. 60.4(2006):535-543.;;Rouhi. ""The Right Stuff: From Research and Development to the Clinic, Getting Drug Crystals right is Full of Pitfalls."" Chem. Eng. News. (2003):32-35.;;Stella et al. ""Prodrugs: Challenges and Rewards, Part 1."" Biotechnology: Pharmaceutical Aspects. (2007):24 (2007).;;U.S. Pharmacopia #23, National Formulary #18. (1995):1843-1844.;;Vippagunt et al. ""Cyrstalline Solids."" Advanced Drug Delivery Reviews. 48(2001):3-26.;;Yu et al. ""Src, a Molecular Switch Governing Gain Control of Synaptic Transmission Mediated by N-methyl-D-Aspartate Receptors."" Proc. Natl. Acad. Sci. USA. 96(1999):7697-7704.;;Zhang et al. ""Design, Synthesis, and SAR of Anthranilamide-Based Factor Xa Inhibitors Incorporating Substituted Biphenyl P4 Motifs."" Bioorg. Med. Chem. Lett. 14.4(2004):983-987.;;Boschelli et al. ""Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity."" J. Med. Chem. 44.23(2001):3965-3977.;;Lesslie et al. ""Combined Activity of Dasatinib (BMS-354825) and Oxaliplatin in an Orthotopic Model of Metastatic Colorectal Carcinoma."" Proc. Am. Assoc. Cancer Res. 47(2006). Abstract #4745.;;Masood et al. ""A Convenient Synthesis of Sendaverine."" Synth. Commun. 10.7(1980):541-544.;;Reagen-Shaw et al. ""Dose Translation from Animal to Human Studies Revisited."" FASEB J. 22(2007):659-661.;;Wilkinson et al. ""Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination."" Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill. Chapter 1(2001):3-29.;;Yezhelyev et al. ""Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice."" Clin. Cancer Res. 10(2004) :8028-8036.",ACTIVE
48,CN,A,CN 102905700 A,186-941-838-342-726,2013-01-30,2013,CN 201180025212 A,2011-03-11,US 2011/0028202 W;;US 32486610 P,2010-04-16,Compositions and methods for the prevention and treatment of cancer,The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.,KINEX PHARMACEUTICALS LLC,HANGAUER JR DAVID G;;CIESIELSKI MICHAEL J;;FENSTERMAKER ROBERT A,,https://lens.org/186-941-838-342-726,Patent Application,no,1,3,14,14,0,A61K31/137;;A61K31/137;;A61K31/5377;;A61K31/4418;;A61K31/4418;;A61K31/496;;A61K31/496;;A61K31/5375;;A61K31/5375;;A61P35/00,A61K31/137;;A61K31/4418;;A61K31/496;;A61K31/5375;;A61P35/00,,0,0,,,,DISCONTINUED
